evipedia.ai
← Back

Dihydromyricetin for Skin Rejuvenation

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: Ampelopsin, DHM, DMY, Dihydroampelopsin, Epicelline

Motivation

Dihydromyricetin (ampelopsin) is a plant compound — one of the natural pigments that color leaves and fruit — concentrated in vine tea, a shrub brewed as a drink in southern China, and in the Japanese raisin tree. It has been sold for years as an oral supplement and has recently become the active ingredient in facial serums. The interest in it for skin rests on a specific claim: that it loosens the chemical tags which build up on the genetic material of aging skin cells and quiet the genes those cells need to renew themselves.

Vine tea has a long folk history, and the compound first reached wider attention as an aid after drinking alcohol. Its move into skin care is recent. A large cosmetics manufacturer screened thousands of natural substances, picked dihydromyricetin for its ability to soften those tags, and built it into serums now sold worldwide. Laboratory estimates of the skin’s biological age are used to judge whether it works.

This review examines dihydromyricetin applied to the skin, and used orally, for skin rejuvenation: the proposed mechanism, the evidence behind each claimed benefit, the risks and the gaps, the protocols in use, and who produced the evidence.

Benefits - Risks - Protocol - Conclusion

High-level overviews of dihydromyricetin and of the epigenetic (gene-switching, without any change to the genes themselves) skin-aging mechanism it is proposed to act on.

No item from the six priority platforms is listed above. Searching each site by name and by domain returned hits on foundmyfitness.com only — an alcohol topic page and two podcast episodes, all treating dihydromyricetin as a hangover aid — none of which discusses skin or the epigenetic mechanism, so none gives a high-level overview of this topic.

Grokipedia

  • Ampelopsin

    Grokipedia files the compound under its other accepted name, covering chemistry, plant sources, pharmacokinetics, preclinical work and safety; it does not address the skin or epigenetic application.

Examine

No Examine article exists for dihydromyricetin. Searching examine.com for both “dihydromyricetin” and “ampelopsin” returns no results, and no dedicated supplement page exists under either name.

ConsumerLab

  • Dihydromyricetin (DHM) – Does It Help and Is it Safe?

    ConsumerLab’s standing answer on the supplement, covering liver, blood sugar, cholesterol, hangover and arthritis claims plus product concerns; the evidence summary is member-gated, and the article does not address skin.

Systematic Reviews

Pooled evidence on dihydromyricetin, none of which addresses a skin outcome.

This body of work covers only the claimed metabolic effect. Neither side of the trade-off central to this review is represented: no systematic review or meta-analysis exists for any skin outcome of dihydromyricetin, and none exists for its principal risk, the long-term consequence of sustained loss of methylation in skin.

Mechanism of Action

Dihydromyricetin is a flavanonol, a flavonoid (plant pigment compound) subclass, formula C₁₅H₁₂O₈. Its proposed skin mechanism is epigenetic. DNA methyltransferase 1, or DNMT1 (the enzyme copying methylation tags onto each new DNA strand), maintains the tagging pattern through cell division. With age that pattern drifts, and genes needed for keratinocyte (surface skin cell) vitality accumulate tags and fall silent. A screen of 1,800 natural substances identified dihydromyricetin as a mild DNMT1 inhibitor, and treated keratinocytes showed modest methylation loss and a lower predicted biological age, per the Beiersdorf discovery study, whose sponsor sells the resulting serum.

Competing explanations exist. It is a strong antioxidant, activating Nrf2 (a master switch for antioxidant genes) and suppressing NF-κB (a switch for inflammation genes), so improvement could be anti-inflammatory rather than epigenetic. It also binds RAGE, the receptor for advanced glycation end products (sugar-damaged proteins that stiffen collagen), which would preserve collagen without touching methylation, per a 2025 rodent study. A third reading is formulation: the serum also carried hyaluronic acid.

Key pharmacological properties, per a 2025 metabolism review: selectivity is low — DNMT1, Nrf2, NF-κB and RAGE are all engaged; oral bioavailability (the share of a dose reaching the bloodstream) is roughly 4%; half-life (the time for blood levels to halve) is one to two hours; clearance runs through sulfation and glucuronidation (the liver’s excretion-tagging route), not cytochrome P450 (the main drug-metabolizing liver enzymes); an intestinal pump limits absorption. Topically it stays in the stratum corneum and upper epidermis (the outer skin layers).

Historical Context & Evolution

Vine tea, Ampelopsis grossedentata (also classified as Nekemias grossedentata), has been brewed for centuries in southern China as a beverage and folk remedy for fever, sore throat and liver complaints; the Japanese raisin tree, Hovenia dulcis, carries the same compound and appears in East Asian texts as a post-drinking remedy. The original intended use was dietary and aimed at the liver, not cosmetic.

The compound entered Western research in 2012, when a University of California group reported in an animal study of alcohol intoxication that dihydromyricetin blocked alcohol’s action at the benzodiazepine site (benzodiazepines being the classic sedative and anti-anxiety medicines) of the GABA-A receptor (the brain’s main calming receptor), and reduced voluntary drinking in rats. That finding, not any skin work, created the supplement market. Human work followed in metabolic medicine: a 2015 randomized controlled trial (participants assigned by chance to the compound or to a dummy treatment) found improvements in liver enzymes and insulin resistance in fatty liver disease.

The skin application arrived only in 2023, out of a compound screen for methyltransferase inhibitors rather than traditional use. It reached the market in 2024 as the branded active in a cosmetic serum, was presented that year at a manufacturer-funded satellite symposium during a European dermatology congress by speakers disclosing consultancy fees from the sponsor, and was extended to a mass-market brand in 2025. Opinion here has not reversed so much as jumped category, and the earlier liver and alcohol findings remain open rather than superseded.

Expected Benefits

High 🟩 🟩 🟩

Improved Liver Enzymes and Glucose–Lipid Markers with Oral Use ⚠️ Conflicted ⭕️ Not Central to Skin Rejuvenation

Oral dihydromyricetin improves validated liver and metabolic markers. A 2015 placebo-controlled trial at 600 mg daily lowered alanine aminotransferase and gamma-glutamyl transferase (liver stress enzymes), glucose and low-density lipoprotein cholesterol in fatty liver disease; a 2026 twelve-month trial repeated the enzyme effect and cut liver stiffness, though that capsule also held vitamins and choline. A network meta-analysis ranked it useful for one lipid only. It bears on liver and metabolic health, touching skin only through glycation. Net reading: replicated, but weaker than rival polyphenols and not for the compound alone.

Magnitude: Combined normalization of alanine aminotransferase and gamma-glutamyl transferase reached 35% versus 5% on placebo at twelve months (p = 0.028; p is the probability that a difference this large would arise by chance alone).

Medium 🟩 🟩

No benefit reaches Medium: the qualifying class of evidence — a single controlled trial measuring a skin clinical endpoint or a validated clinical surrogate for skin — does not exist for this compound.

Low 🟩

Reduced Wrinkle Visibility and Surface Roughness

Twice-daily application of a dihydromyricetin serum reduced wrinkle depth and surface irregularity in an 8-week single-arm study of 60 adults aged 20–59 spanning six Fitzpatrick phototypes (the standard scale of skin tone and sun sensitivity). Measurement was instrumental, not self-reported. The study had no dummy-serum arm and was manufacturer-funded.

Magnitude: At 8 weeks the wrinkle visibility coefficient fell 13.9% and occupancy rate 12.3% (both p < 0.001), with 86.4% of subjects improving; surface roughness fell 4.3% and 5.4% on the two profilometry (three-dimensional surface mapping) measures (p < 0.05).

Increased Dermal Density, Firmness and Elasticity

In the same 8-week product-use study, ultrasound showed denser tissue in the dermis (the deeper skin layer), and blinded dermatologist grading found firmer, more elastic skin. The proposed basis is reactivation of silenced matrix genes plus the formulation’s hyaluronic acid. The uncontrolled design leaves base and active inseparable.

Magnitude: Dermal echogenicity (the ultrasound brightness used as a density proxy) rose 7.7% at 4 weeks and 10.4% at 8 weeks (p < 0.001); expert-graded tactile elasticity improved 14.2% and firmness 9.8%.

Improved Skin Radiance and Perceived Skin Age

Blinded expert grading in the same cohort recorded brighter skin and a lower estimated visual skin age. Radiance moved more than any other visually graded parameter, and is also the parameter most sensitive to hydration and to any well-formulated serum. Participants’ own assessments agreed with the graders.

Magnitude: Radiance and luminosity scores improved 19.6% and expert-rated skin age 6.5% at 8 weeks (both p < 0.001).

Reduced Next-Day Impairment after Alcohol ⭕️ Not Central to Skin Rejuvenation

Oral dihydromyricetin is sold mainly to blunt alcohol aftereffects, and a 2026 observational cohort of 90 adults on a multi-ingredient blend recorded better next-day energy, clarity and sleep. A 2026 systematic review found isolated-compound human evidence almost absent. It bears on alcohol recovery, not appearance.

Magnitude: Next-day mental clarity, physical well-being, energy and sleep quality each improved on a 1–10 scale against alcohol-only nights (β = 0.26–0.36, the modeled score gain on that scale; all p ≤ 0.002), with small standardized effect sizes (Cohen’s d 0.20–0.32).

Speculative 🟨

Reduction in Epidermal Epigenetic Age

Tape-strip sampling (lifting surface cells on an adhesive strip) before and after the 8-week protocol showed methylation age falling 2.1 years. Basis is an unvalidated biomarker in an uncontrolled study.

Suppression of Melanin Formation

In mouse pigment-cell cultures dihydromyricetin reduced tyrosinase (the enzyme building melanin) activity and melanin content by damping three kinase relays (enzymes that pass signals inward). Basis is laboratory work alone; no human pigmentation study exists.

Protection of Skin Cells from Ultraviolet Damage

Pre-treatment protected cultured human keratinocytes against ultraviolet-A damage, and nanocapsule hydrogels blocked ultraviolet-B DNA lesions in a cell model. Both are laboratory systems. No human photoprotection trial has been run.

Anti-Glycation and Collagen Preservation

Rats given dihydromyricetin during accelerated aging retained more skin collagen and elasticity, and the compound bound RAGE tightly. Evidence is animal and laboratory only; human relevance was not measured.

Senescence Modulation in Skin Fibroblasts ⚠️ Conflicted

A 2026 screen found it calms senescent (worn-out, non-dividing) fibroblasts yet kills senescent brain immune cells; an earlier study slowed aging markers in human skin fibroblasts. Net reading: direction is cell-type dependent, untested in skin.

Suppression of Inflammatory Skin Disease Activity ⭕️ Not Central to Skin Rejuvenation

Dihydromyricetin calmed psoriasis-like inflammation in imiquimod-treated mice and killed acne bacteria while damping keratinocyte inflammation. It bears on inflammatory skin disease, not appearance. Animal and laboratory work only.

Accelerated Wound Healing ⭕️ Not Central to Skin Rejuvenation

Delivered in nanoparticles, it sped closure of diabetic wounds in mice and burn wounds in rats. It bears on wound repair, not appearance, though collagen deposition rose. Basis is animal work with engineered carriers.

Benefit-Modifying Factors

  • Conjugation-enzyme variants: UGT and SULT variants (these enzyme families attach sugar or sulfate groups so a compound can be excreted) change how fast an oral dose is cleared; slow conjugators reach higher blood levels. No variant has been linked to topical response.
  • Baseline epigenetic age acceleration: Skin whose methylation age already exceeds its owner’s chronological age carries more reversible silencing to recover, and in the pivotal study 40% of users accounted for most of the total age reduction.
  • Baseline visible damage: Every endpoint was expressed as change from each person’s own starting point, so heavily sun-damaged skin has more headroom than skin that is already smooth and dense.
  • Sex: Both sexes improved on every clinical parameter, but men were underrepresented in the only clinical study, so no sex-specific effect size can be stated.
  • Skin tone and phototype: Response did not differ across phototypes I to VI, which is unusual for a cosmetic active and is the central claim of the multi-ethnic study design.
  • Pre-existing conditions: Diabetes and poor blood-sugar control raise the glycation load on collagen, one of the pathways the compound is proposed to act on; barrier disease such as eczema alters penetration instead.
  • Age: The clinical cohort spanned 20 to 59 years, with flat response across five-year bands. Nothing is known above 59, where thinner skin changes both penetration and tolerance.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the qualifying class of evidence — a documented adverse event or validated marker of harm recorded in more than one controlled human trial — does not exist, because only three small controlled oral trials have been run and none published an itemized adverse-event table.

Medium 🟥 🟥

No risk reaches Medium either: the qualifying class of evidence — a specific adverse outcome recorded in a single controlled trial or in consistent observational data — is absent, since the human safety record consists of unquantified tolerability statements and no post-marketing reporting system (the channels that collect adverse reports after sale) covers cosmetic actives.

Low 🟥

Application-Site Irritation and Contact Sensitization

A facial serum carrying an active plant compound can provoke stinging, redness or delayed contact allergy, more so when layered with other irritant actives. The 8-week study in 60 adults recorded no product-related adverse events, which is reassuring but comes from a manufacturer-run single-arm design.

Magnitude: Zero product-related adverse events among 60 users over 8 weeks of twice-daily facial and neck application; no incidence figure for contact sensitization to dihydromyricetin exists in the literature.

Gastrointestinal Intolerance with Oral Dosing

Oral plant compounds commonly cause nausea, bloating or loose stools, and poor solubility keeps most of an oral dose in the gut. The twelve-month trial at 300 mg daily lost nine of 55 participants, attributed to personal reasons; the systematic review found no safety signal but no systematic collection.

Magnitude: Not quantified in available studies. No trial of dihydromyricetin has published an adverse-event table, so the rate of digestive complaints at the doses used cannot be separated from background.

Speculative 🟨

Cancer Risk from Loss of DNA Methylation ⚠️ Conflicted

Mechanistic concern: broad loss of methylation can destabilize a genome. Screening of treated keratinocytes found no reactivation of skin cancer genes, per the pivotal study. Net reading: theoretical, with no supporting human or cell data.

Unintended Loss of Pigment

Because the compound suppresses tyrosinase in cultured pigment cells, sustained use could in principle lighten skin or blunt tanning. No human depigmentation is reported, and cell concentrations far exceeded serum delivery.

Suppression of Androgen Signaling

In a rat prostate model oral dihydromyricetin suppressed 5α-reductase (the enzyme converting testosterone to its potent form), which governs sebum (skin oil) and hair growth. Basis is one animal study; no human hormone data exist.

Reduced Platelet Reactivity

Diabetic mice given dihydromyricetin showed dampened platelet activation through lower oxidative stress inside the platelets. Isolated animal evidence only, but it is the mechanism that would matter before a skin procedure or surgery.

Gut Bacterial Shifts with Oral Dosing

Because most of an oral dose stays in the gut, oral use reshapes bacterial populations there, as mice on high-dose dihydromyricetin showed. The shift was favorable in that model; no human microbiome measurement exists.

Risk-Modifying Factors

  • Conjugation-enzyme variants: Slow UGT or SULT conjugators clear an oral dose less efficiently and reach higher blood levels, which is where any hormonal or platelet effect would surface first.
  • Baseline liver enzymes: Raised alanine aminotransferase or gamma-glutamyl transferase at the outset masks any later drift, since the compound is promoted for liver benefit and a worsening trend would otherwise pass unnoticed.
  • Baseline barrier status: A compromised skin barrier from eczema, rosacea (a facial redness disorder) or recent resurfacing raises both penetration and irritation risk from any facial serum.
  • Sex: No sex difference in adverse effects has been reported, but men were a minority in the only topical study and absent from most oral trials, leaving male-specific risk untested.
  • Pre-existing conditions: Hormone-sensitive conditions, bleeding disorders and planned surgery are the settings in which the animal-level androgen and platelet findings would matter most.
  • Age: Thinner, drier skin above 70 and the multiple-medication load typical of that group raise both irritation risk and the chance of a transporter-level drug interaction with oral use.

Key Interactions & Contraindications

  • Transporter substrates (rosuvastatin, atorvastatin, fexofenadine, valsartan): Caution — raised drug levels. Circulating relatives of dihydromyricetin inhibit OATP1B1 and OATP2B1 (transporters pulling drugs into liver and gut cells), per a 2024 enzyme and transporter study; protocols separate oral doses by four hours.
  • Efflux-pump inhibitors (verapamil, ketoconazole, ciclosporin): Monitor — roughly doubled dihydromyricetin exposure. These block the intestinal pump that normally expels it, raising oral bioavailability from about 4% to 7%, per a rat pharmacokinetic study; low-end oral dosing is the usual adjustment.
  • Cytochrome P450 substrates (midazolam, warfarin, clopidogrel): Caution — theoretical accumulation. Direct testing found no or minor inhibition of CYP2C9, CYP2C19 and CYP3A4 (three of those drug-clearing liver enzymes), per the same 2024 study, so monitoring rather than avoidance applies.
  • Benzodiazepines and non-benzodiazepine sleep medicines (diazepam, alprazolam, zolpidem): Caution — blunted sedative and anxiety-reducing effect. Dihydromyricetin competes at the same receptor site; protocols keep the two at least four hours apart.
  • Acetaminophen (paracetamol): Monitor — masked liver injury. Animal work shows dihydromyricetin blunts acetaminophen liver damage, per a 2026 review of botanicals; the effect is protective, but could delay recognition of an overdose.
  • Alcohol: Caution — masked impairment. The compound reduces the subjective feel of intoxication without removing the impairment, which invites heavier drinking; this interaction is the reason most supplements containing it exist.
  • Blood-sugar-lowering medicines (metformin, glipizide, insulin): Monitor — hypoglycemia (blood sugar falling too low). Oral dihydromyricetin lowers fasting glucose in its own right, so more frequent glucose checks during the first month are the standard precaution.
  • Blood thinners and antiplatelet medicines (warfarin, clopidogrel, aspirin): Caution — additive bleeding risk from the animal platelet finding. Two weeks off oral dosing before surgery or any needling procedure is the usual mitigation.
  • Supplements with additive blood-sugar lowering (berberine, chromium, alpha-lipoic acid, bitter melon): Monitor — hypoglycemia. Stacking these with oral dihydromyricetin can push fasting glucose below target, particularly alongside fasting protocols.
  • Supplements competing for the same clearance routes (quercetin, myricetin, green tea catechins, curcumin, resveratrol): Caution — unpredictable mutual accumulation. All saturate the same conjugating enzymes and transporters; separating intake across the day rather than stacking is the standard mitigation.
  • Topical retinoids (tretinoin, adapalene, retinol), exfoliating acids (glycolic, salicylic) and benzoyl peroxide: Caution — multiplied irritation and barrier damage. Retinoids (the vitamin A–derived skin medicines) are the main driver; alternating morning and evening application rather than layering is the conventional approach.
  • Procedural treatments (fractional laser, microneedling, chemical peel): Monitor — irritation and pigment change. Practitioners combine the serum with these to exploit overlapping gene reactivation, but applying an active onto freshly wounded skin is deferred until the surface has healed.

Populations who should avoid Dihydromyricetin:

  • Pregnant and breastfeeding women, since no reproductive toxicity data exist for the compound in any form
  • Anyone with a history of melanoma or non-melanoma skin cancer within the treatment field, given the unresolved theoretical demethylation concern
  • People with active eczema, a rosacea flare or a broken skin barrier in the application area, until the barrier has recovered
  • Anyone within 14 days of planned surgery, injectables or needling, and within 90 days of a full-face resurfacing procedure, for oral use
  • People with a documented plant-compound or vine tea contact allergy
  • Children and adolescents under 18 years, for whom no data of any kind exist

Risk Mitigation Strategies

  • Pre-use patch testing: Protocols apply the serum to a 2 cm test area on the inner forearm twice daily for five days before facial use, which catches contact sensitization before it reaches the whole face.
  • Single-active introduction: The serum is introduced alone for four weeks before other actives return, so that any irritation is attributed correctly rather than blamed on the wrong product.
  • Alternating irritant actives: Morning serum with evening retinoid, rather than layering, prevents the additive barrier disruption that drives most cosmetic dropouts.
  • Daily high-protection sunscreen: The clinical protocol applied a factor 50 or higher sunscreen over the serum each morning, offsetting both the theoretical pigment-suppression effect and ordinary sun-driven aging.
  • Baseline and 12-week liver panel for oral use: Alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase measured before starting and again at 12 weeks make any liver change visible rather than assumed benign.
  • Oral dosing capped at trial levels: 600 mg daily is the ceiling tested in controlled trials; nothing above it has been examined in humans for either efficacy or safety.
  • Two-week oral break before procedures: Stopping oral dihydromyricetin 14 days before surgery, injectables or needling removes any additive antiplatelet effect suggested by the animal data.
  • Four-hour separation from transported drugs: Spacing oral doses from statins (cholesterol-lowering medicines), fexofenadine or benzodiazepines limits the transporter and receptor-site interactions listed above.
  • Glucose self-monitoring in month one: Twice-weekly fasting glucose for four weeks after starting oral dosing, in anyone on blood-sugar-lowering medication, catches additive hypoglycemia early.

Therapeutic Protocol

  • Standard topical regimen: A dihydromyricetin serum applied twice daily, morning and night, to clean dry skin of the whole face and neck, followed each morning by a factor 50 or higher sunscreen, as in the manufacturer’s clinical study.
  • Popularized by: Beiersdorf’s research group working with Frank Lyko’s epigenetics laboratory at Heidelberg University developed and commercialized the topical approach; the branded active reached market in a cosmetic serum in 2024.
  • Competing approach, prescription retinoid: Topical tretinoin carries the largest controlled-trial base for fine wrinkles, pigmentation and texture, popularized by Albert Kligman’s Pennsylvania group; its limitation is irritation, the gap the epigenetic serum targets.
  • Competing approach, procedural combination: Firas Al-Niaimi and Hassan Galadari describe pairing the serum with fractional laser, microneedling or chemical peel at a manufacturer-funded dermatology symposium, arguing that both reactivate overlapping youth-associated genes.
  • Competing approach, oral supplementation: 300–600 mg daily is the range tested in fatty liver trials. No oral protocol has ever been tested against a skin outcome, so this route is extrapolation rather than evidence.
  • Best time of day: Topical application splits morning and night, the morning dose sitting under sunscreen. Oral doses are taken with a fat-containing meal, which improves absorption of a poorly soluble compound.
  • Half-life: Roughly one to two hours after oral dosing, which is why oral regimens split the daily amount. Topical exposure is governed by the twice-daily application rather than by blood half-life.
  • Single versus split dosing: Oral trials used two capsules twice daily rather than one large dose. The short half-life and saturable absorption make splitting the rational default.
  • Genetic considerations: No pharmacogenetic test — none matching a gene variant to a dose — guides this compound. UGT and SULT variants affect oral clearance in principle, and phototype did not alter topical response.
  • Sex differences: No sex-specific dose has been established. Both sexes improved on every topical parameter, and oral trials in fatty liver enrolled both sexes without reporting separate effect sizes.
  • Age considerations: The topical protocol was tested from 20 to 59 years with equal response across five-year bands. Above 59, protocols introduce it once daily on thinner skin before moving to twice daily.
  • Baseline biomarker considerations: Higher baseline epigenetic age acceleration and greater visible sun damage predict a larger measured change, since every endpoint is expressed as change from the individual’s own baseline.
  • Pre-existing condition considerations: In active barrier disease, protocols delay the start until the skin is calm. Diabetes raises the glycation load on collagen, one of the pathways the compound is proposed to interrupt.

Discontinuation & Cycling

  • Duration of use: Topical use is framed as continuous and open-ended, as with any cosmetic active. Methylation patterns drift back once mild inhibition stops, so the effect is not expected to outlast discontinuation.
  • Withdrawal effects: None reported for either route. The compound has no dependence liability, and no rebound worsening of skin parameters has been described after the serum is stopped.
  • Tapering: No taper applies to topical use. For oral use at 300 mg daily, abrupt cessation is unproblematic, and a fasting glucose recheck is the usual follow-up in anyone on blood-sugar-lowering medication.
  • Cycling: No cycling protocol has been tested. The proposed mechanism depends on continuous mild enzyme inhibition, so scheduled breaks would be expected to reduce rather than preserve the effect.
  • Longest tested exposure: Eight weeks topically and twelve months orally. Nothing is known about continuous topical use beyond two months, which is the main practical gap in the discontinuation picture.

Sourcing and Quality

  • Cosmetic serums: The clinically tested formulation is the branded active in the Eucerin Hyaluron-Filler Epigenetic Serum and the NIVEA Cellular Epigenetics Rejuvenating Serum. Cosmetic labels give no concentration, so matching the tested product matters more than the ingredient name.
  • Ingredient position on the label: Dihydromyricetin appearing near the end of an ingredient list, after preservatives, signals a token inclusion. The tested serum also contained two molecular weights of hyaluronic acid and an enzyme blocker that slows its breakdown.
  • Oral supplement purity: A certificate of analysis stating dihydromyricetin content by high-performance liquid chromatography is the relevant document, since products sold as vine tea extract vary widely in actual content.
  • Third-party testing: Certification marks from NSF International, U.S. Pharmacopeia or Informed Choice, or an independent laboratory report, carry the assurance; no regulator verifies the content of a dihydromyricetin supplement in any market.
  • Formulation and stability: The compound is poorly water-soluble and degrades with heat and light, and unstabilized preparations yellow on storage, per a topical formulation study; nanocapsule and self-dispersing forms were built to address this.
  • Source plant: Material from Ampelopsis grossedentata leaf is the most common and best characterized. Hovenia dulcis extracts contain the compound alongside other constituents and are not interchangeable by weight.
  • Multi-ingredient hangover blends: These stack the compound with cysteine, electrolytes and B vitamins at undisclosed doses, which makes both the delivered dose and any adverse effect impossible to attribute.

Practical Considerations

  • Time to effect: Instrumental wrinkle and dermal-density changes were already significant at four weeks and larger at eight, with texture and radiance moving fastest. Nothing is known beyond eight weeks.
  • Common pitfall, expecting a retinoid-scale result: The measured changes run from a few percent to about twenty percent on instrument scales, which is visible in measurement but modest to the eye across two months.
  • Common pitfall, assuming oral works for skin: Every skin finding comes from topical application. Oral bioavailability is roughly 4%, and no oral trial has measured any skin endpoint.
  • Common pitfall, dropping sunscreen: The clinical protocol included high-protection sunscreen daily. Sunscreen did not produce the effect, but the protocol was never tested without it.
  • Regulatory status: Sold as a cosmetic ingredient and as a dietary supplement, and not an approved drug in any jurisdiction, so no efficacy claim has been reviewed by a regulator and no prescribing information exists.
  • Cost and accessibility: Both the serum and oral capsules are inexpensive and available without prescription.
  • Payer incentives: No insurer or national health system reimburses cosmetic skin-aging treatment anywhere, so institutional payers have no financial stake in serum versus generic prescription retinoid; that absence also means no payer funds independent comparative trials, leaving manufacturers as the sole source of clinical data.

Interaction with Foundational Habits

  • Sleep: Indirect and potentially blunting for anyone using a sleep aid. Dihydromyricetin competes at the benzodiazepine site of the GABA-A receptor, so oral doses can weaken prescribed sedatives; it is not itself sedating, and topical use has no known sleep interaction. Bedtime is also when the serum’s second daily dose is applied.
  • Nutrition: Direct and potentiating. Oral absorption of this poorly soluble compound improves with a fat-containing meal, which is why self-dispersing formulations exist. A diet heavy in browned and cooked foods raises the advanced glycation load that the compound’s RAGE binding is proposed to counter.
  • Exercise: Indirect, with no known blunting. No evidence suggests interference with training adaptation, and an animal study of exercise-induced muscle damage points the other way. Practically, sweat and friction strip topical actives, so application follows training rather than preceding it.
  • Stress management: Indirect. Lifestyle and physiological factors shift skin methylation age in both directions, per a 2026 analysis of 851 people, so stress reduction acts on the same mechanism from the other side. No direct effect of the compound on cortisol has been measured in humans.

Monitoring Protocol & Defining Success

Baseline documentation precedes the first application. For topical use that means standardized photographs of the same facial areas under identical lighting and time of day, plus a record of current texture, firmness and radiance; a tape-strip epigenetic skin age test, offered by research-linked clinics, reproduces the measure the pivotal study used. Oral use adds a baseline liver panel, fasting glucose and glycated hemoglobin, since the compound moves all three. Ongoing monitoring follows the cadence of the clinical protocol: photographs and instrument measures at 4 weeks and 8 weeks, then every 3 months; liver and glucose panels at 12 weeks for oral use, then every 6–12 months. Success is defined as sustained change from the individual’s own baseline rather than a value relative to a population reference.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Epidermal DNA methylation age No established target; track change from own baseline, with a value below chronological age as the goal The measure the pivotal study used to claim rejuvenation Tape-strip sampling; research and specialist clinics only, not a routine laboratory test
Standardized facial photography No established target; track percentage change in wrinkle and texture scores from own baseline The only endpoint reflecting what is actually visible Same lighting, angle and time of day; skin clean and unmoisturized for at least an hour beforehand
Dermal echogenicity No established target; track percentage change from own baseline Objective measure of density in the deeper skin layer, the most consistent mover in the clinical study High-frequency ultrasound at a dermatology clinic; same cheek site each time
Alanine aminotransferase 10–26 U/L in women, 10–33 U/L in men Detects liver-cell stress during oral use Conventional laboratories flag only above roughly 40 U/L, which misses early drift; fasting not required
Gamma-glutamyl transferase Below 20 U/L Sensitive early marker of oxidative and bile-duct stress Conventional upper limits run to 50–60 U/L; raised by alcohol, so intake is recorded alongside
Glycated hemoglobin 4.8–5.4% Glycation of collagen is one of the skin-aging pathways the compound targets Glycated hemoglobin reflects average blood sugar over roughly three months; conventional cut-off is below 5.7%
Fasting glucose 75–86 mg/dL Oral dosing lowers it, so additive hypoglycemia appears here first Conventional normal extends to 99 mg/dL, so values well above the functional target pass unflagged; drawn fasting, 8–12 hours; paired with glycated hemoglobin for a fuller picture
High-sensitivity C-reactive protein Below 0.5 mg/L Low-grade inflammation accelerates visible skin aging High-sensitivity C-reactive protein is a general marker of body-wide inflammation; conventional cut-off is below 3.0 mg/L; repeat if drawn during an infection
25-hydroxyvitamin D 40–60 ng/mL The protocol’s daily high-protection sunscreen reduces skin synthesis over months Conventional sufficiency starts at 30 ng/mL; end-of-winter draw captures the true trough

Qualitative markers tracked alongside the laboratory values:

  • Morning skin feel: tightness, roughness or comfort on waking
  • Makeup behavior: whether foundation settles into lines less than before
  • Perceived radiance in daylight rather than in bathroom lighting
  • Tolerance signals: stinging, flushing or peeling after application
  • Unprompted comments from other people, which track visible change better than self-assessment

Emerging Research

  • Phase 1 dose escalation in alcohol-associated liver disease: NCT05623501, a University of Southern California study of 12 participants, registry status unknown, with pharmacokinetics and adverse events as primary endpoints. It is the only registered study that would yield formal human safety and exposure data for isolated dihydromyricetin.
  • Stress-induced sleep deficits: NCT05280561, a completed University of Southern California study of 288 participants measuring sleep duration and stress. Its size makes it the largest human exposure on record, and its tolerability data bear directly on oral use.
  • Blood-sugar control in type 2 diabetes: NCT03606694, a phase 2 University of Guadalajara study of 24 participants, registry status unknown, with fasting glucose, glycated hemoglobin and insulin secretion as endpoints. It would test the metabolic claim outside its original Chinese trial setting.
  • Post-alcohol recovery products: NCT06575972 and NCT05757089, industry-sponsored studies of 60 participants each measuring hangover severity. Both test multi-ingredient blends, so neither can attribute an effect or an adverse event to dihydromyricetin itself.
  • No registered trial targets skin: A registry search for dihydromyricetin and ampelopsin returns five studies, none with a skin endpoint. The topical evidence therefore sits entirely outside the registered-trial system, which weakens rather than strengthens the case.
  • The missing dummy-controlled skin trial: Qi et al., 2026 name the absent vehicle arm among the limitations of the pivotal study. A serum-base comparison would either confirm the active or reassign the benefit to the formulation, and is the single result most likely to change current understanding.
  • Epigenetic age as an outcome measure: Bienkowska et al., 2026 analyzed 851 people and placed dihydromyricetin among interventions associated with decelerated skin methylation aging, while cautioning that causality needs interventional designs. Independent replication outside the manufacturer would strengthen the case.
  • Senotherapeutic direction: Xu et al., 2026 report the compound calming worn-out fibroblasts but killing worn-out brain immune cells, through peroxiredoxin 2 (an antioxidant protein assisting DNA repair). Opposite effects by cell type complicate any claim of a uniformly benign profile.
  • Delivery systems: Work reviewed by Hou et al., 2025 on nanocarriers and self-dispersing formulations targets the roughly 4% oral bioavailability. If solved, an oral route could be tested against skin endpoints for the first time.

Conclusion

Dihydromyricetin is a plant compound from vine tea, long used as a drink and a folk remedy, repurposed as the active ingredient in facial serums on the argument that it loosens the chemical tags which silence genes in aging skin cells. The idea is biologically plausible and the laboratory work behind it is careful.

The human skin evidence, however, is a single short study with no comparison group, conducted and funded by the company that sells the serum and staffed largely by its employees. That company’s financial interest in the result is direct, and the same group produced most of the surrounding literature, including the review articles and the industry-funded conference session at which the approach was presented to dermatologists. The measured improvements in wrinkle depth, surface smoothness, skin thickness and brightness were real and instrument-based, but modest, and they cannot be separated from the serum’s other ingredients or from the sunscreen applied alongside.

The safety picture is quiet rather than clean. No side effects were recorded, but no study has collected them systematically, and the concerns that do exist — loss of pigment, hormone and blood-clotting effects, the theoretical consequence of loosening genetic tags — rest on animal and cell work alone. The firmer evidence for this compound concerns liver and blood-sugar markers, which is a different question from how skin looks. For someone tracking measurable change against their own starting point, the uncertainty here is about attribution rather than about harm.

Top - Benefits - Risks - Protocol